Navigation Links
Families of SMA Releases Newsletter Describing the Scientific Strategy Behind Antisense Drugs for Spinal Muscular Atrophy
Date:12/9/2013

Elk Grove Village, IL (PRWEB) December 09, 2013

Families of SMA has released a new edition of the Compass Newsletter, a publication dedicated to research updates. This newsletter was produced in a collaboration between Families of SMA, Biogen Idec, and Isis Pharmaceuticals. It describes the scientific strategy behind Antisense Drugs. It also provides updates on the ongoing research and clinical trials for this class of SMA drugs.

This edition of Compass, includes information about:

-The ABC's of Antisense Drugs

-ISIS-SMNRX Program Update on Ongoing and Future Clinical Trials

-FSMA Grant Award to Dr. Adrian Krainer at CSHL to Assess Influence of Backbone Chemistry on Antisense Drugs

-FSMA Grant Award to Drs. Arthur Burghes and Christian Lorson for Novel Antisense Therapies

-Report on New Data from the Completed Phase I Study Evaluating the Safety of Isis-SMNRX

Antisense drugs are small snippets of synthetic genetic material that bind to RNA (short for ribonucleic acid). The main factor driving where the antisense drug binds to the RNA is the nucleic acid sequence used. Nucleic acids consist of a chain of linked units called nucleotides. Antisense drugs are typically 12-21 nucleotides that are chemically modified to bring about the appropriate drug response.

How does the antisense approach work for SMA?
SMA is caused by a loss of, or defect in, the survival motor neuron 1 (SMN1) gene. The SMN1 gene produces most of the SMN protein, which is critical to the health and survival of the nerve cells in the spinal cord responsible for muscle function. The severity of SMA is correlated with the amount of SMN protein in the cell. A second closely related back-up gene called SMN2 exists that normally produces a truncated, low-functioning form of SMN protein. Antisense therapy could be used to change the functioning of the SMN2 gene by utilizing alternative RNA splicing. Alternative splicing is a normal mechanism that the cell uses to produce different, but closely related proteins from a single gene.

About Families of SMA
Families of SMA has awarded four new drug discovery projects since the start of 2013. The research progress provides hope that one day we will live in a world without SMA. There are now 15 new SMA drug programs in development, including 4 in clinical trials. This pipeline has expanded from just 4 programs 5 years ago. Families of SMA has funded over half of all the ongoing drug programs for SMA. The FSMA research approach funds programs at early stages, and then partners with companies to take them through clinical trials. Supporting multiple programs gives different approaches for a SMA therapy, which increases the chances of success and accelerates the timeline to a treatment and cure.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11401483.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Super-Sod is Donating their Doc's Raised Garden Kits to Families and Community Gardens
2. Families Grateful for At-work Access to Youth Cardiac, Concussion Screenings
3. Narconon International Publishes Indispensible Guide for Families Dealing with Addiction
4. IBT’s Top Ten Holiday Tips Minimize Challenges for Children with Autism and Their Families
5. A New Website for Families to Turn: New Health and Wellness Promotion Website Launched by Family Voices
6. YMCA Thanksgiving Dinner Supports Families in Need
7. 1-800-HOMECARE Comments on Recent Nursing Home Theft That Strikes Seniors andFamilies
8. STAR Center Raising Funds for Special Needs Children of Military Families
9. Princeton study: Military children and their families remain an invisible subculture
10. Researchers at Pace University Explore the Lived Experiences of Families Members That Have the Possible Risk of Genetic Mutations That Cause Sudden Cardiac Death
11. Families, Businesses & Special Needs Children Rally to Support America's Special Kidz (A.S.K.)'s First Fundraiser
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Apple Rehab ... services, staged a mock evacuation of the facility as part of a disaster drill ... Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... ... , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many ... event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids ... of all ages; it is a non-competitive, non-timed event, which is all about having ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology: